tiprankstipranks
Johnson & Johnson sees ‘above market growth’ in Pharmaceutical segment in FY23
The Fly

Johnson & Johnson sees ‘above market growth’ in Pharmaceutical segment in FY23

Expects 1H23 operational sales growth lower than 2H in Pharmaceutical and expects Q2 stronger than Q1. Expects "continued competitive growth" in MedTech segment, with 1H23 sales growth lower than 2H. Expects FX to have negative impact on results in 1H23 and "potentially favorable" in 2H23. Expects to complete Consumer Health separation in 2023.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on JNJ:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles